New drug MER511 enters first human trial for Graves' disease
Disease control
Recruiting now
This early-stage trial tests a new biologic drug called MER511 in 100 adults with Graves' disease. The main goal is to check safety and side effects, and to see how the body handles the drug when given by IV or injection. Participants must be on stable thyroid medication. The stu…
Phase: PHASE1 • Sponsor: Merida Biosciences • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC